Impact of neutropenia on delivering planned chemotherapy for solid tumours: Original article

European Journal of Cancer Care

Volumn 17, Issue 1, 2008, Pages 19-25

  Khan, S ^a   Dhadda, A ^a   Fyfe, D ^b   Sundar, S ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b ROYAL LANCASTER INFIRMARY   (United Kingdom)

Author keywords

Chemotherapy; Dose delay; Dose reduction; GCSF; Infections; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 37549043541     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2007.00797.x     Document Type: Article

References (27)

1. American Society of Clinical Oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 12, 2471 2508.
2. Bonadonna G., Valagussa P., Moliterni A., Zambetti M. Brambilla C. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. The New England Journal of Medicine 332, 901 906.
3. Budman D.R., Berry D.A., Cirrincione C.T., Henderson I.C., Wood W.C., Weiss R.B., Ferree C.R., Muss H.B., Green M.R., Norton L. Frei E. 3rd 1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. Journal of the National Cancer Institute 90, 1205 1211.
4. Chang J. (2000) Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. European Journal of Cancer 36 (Suppl. 1 S11 S14.
5. Crawford J., Ozer H., Stoller R., Johnson D., Lyman G., Tabbara I., Kris M., Grous J., Picozzi V. Rausch G., et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. The New England Journal of Medicine 325, 164 170.
6. Di Maio M., Gridelli C., Gallo C., et al. (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small cell lung cancer: a pooled analysis of three randomised trials. The Lancet Oncology 6, 669 677.
7. Gabrilove J. (2005) Preventing neutropenia more effective than treating it. Oncology Times XXVII (2 30 31.
8. Gianni A.M. Piccart M.J. (2000) Optimising chemotherapy dose density and dose intensity. new strategies to improve outcomes in adjuvant therapy for breast cancer. European Journal of Cancer 36 (Suppl. 1 S1 S3.
9. Goodman A. (2005) Febrile neutropenia. Why it is still the most serious side effect of cancer treatment. Oncology Times 2, 6 10.
10. Groopman J.E., Molina J.M. Scadden G.T. (1989) Hematopoietic growth factors. Biology and clinical applications. The New England Journal of Medicine 321, 1449 1459.
11. Hryniuk W. Bush H. (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2, 1281 1288.
12. Hryniuk W. Levine M.N. (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. Journal of Clinical Oncology 4, 1162 1170.
13. Link B.K., Budd G.T., Scott S., Dickman E., Paul D., Lawless G., Lee M.W., Fridman M., Ford J. Carter W.B. (2001) Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 92, 1354 1367.
14. Lyman G.H., Kuderer N.M. Djulbegovic B. (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine 112, 406 411.
15. Pettengell R., Gurney H., Radford J.A., Deakin D.P., James R., Wilkinson P.M., Kane K., Bentley J. Crowther D. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80, 1430 1436.
16. Repetto L. Balducci L. (2002) A case for geriatric oncology. The Lancet Oncology 3, 289 297.
17. Repetto L., Biganzoli L., Koehne C.H., Luebbe A.S., Soubeyran P., Tjan-Heijnen V.C.G. Aapro M.S. (2003) EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. European Journal of Cancer 39, 2264 2272.
18. Rivera E., Haim Erder M., Fridman M., Frye D. Hortobagyi G.N. (2003) First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Research 5, R114 R120.
19. Savvides P., Terrin N., Erban J. Selker H.P. (2001) Development and validation of a patient-specific predictive instrument for the need for dose-reduction in chemotherapy for breast cancer. Proceedings of the American Society of Clinical Oncology 20, 244a.
20. Silber J.H., Fridman M., Di Paola R.S., Erder M.H., Pauly M.V. Fox K.R. (1998) First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. Journal of Clinical Oncology 16, 2392 2400.
21. Silvestri F., Velisig M., Fanin R., Virgolini L., Zaja F., Barillari G. Baccarani M. (1995) Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. Leukemia and Lymphoma 16, 465 470.
22. Smith G., Fine M.J., Lenert L.L. Newbold R. (1999) Project chemoInsight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC and CAF. Proceedings of the American Society of Clinical Oncology 18, 78a.
23. Tannock I.F., Boyd N.F., DeBoer G., Erlichman C., Fine S., Larocque G., Mayers C., Perrault D. Sutherland H. (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. Journal of Clinical Oncology 6, 1377 1387.
24. Therasse P., Mauriac L. Welnicka M. (1998) Neo-adjuvant chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase III study comparing FEC vs high dose intensity EC and GCSF. Proceedings of the American Society of Clinical Oncology 17, 124a (abstract 472).
25. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., Depierre A., Johnson P., Decoster G., Tomita D. Ewen C. (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 29A, 319 324.
26. Welte K., Gabrilove J., Bronchud M.H., Platzer E. Morstyn G. (1996) Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88, 1907 1929.
27. Wood W.C., Budman D.R., Korzun A.H., Cooper M.R., Younger J., Hart R.D., Moore A., Ellerton J.A., Norton L., Ferree C.R., Colangelo Ballow A., Frei E. Henderson I.C. (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. The New England Journal of Medicine 330, 1253 1259.